NasdaqGS:VRTXBiotechs
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Fund Exit And Setback For Journavx Pain Label
A prominent investment fund has fully exited Vertex Pharmaceuticals (VRTX) after the company said it does not see a path to a broad neuropathic chronic pain label for Journavx, following discussions with the FDA.
See our latest analysis for Vertex Pharmaceuticals.
Vertex’s share price has shown resilient momentum, with a 90 day share price return of 13.82% and a 1 year total shareholder return of 8.24%, even as mixed news around Journavx shifted some investor focus back to its broader...